Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer.
暂无分享,去创建一个
S. Agelaki | D. Mavroudis | V. Georgoulias | K. Kalbakis | A. Kotsakis | L. Vamvakas | E. Tsaroucha | P. Papakotoulas | N. Androulakis | M. Veslemes | G. Pavlakou | M. Agelidou | A. Agelidou | S. Baka | A. Gerogianni
[1] J. Crowley,et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] L. Ek,et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] T. Ciuleanu,et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] N. Hanna,et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] D. Mavroudis,et al. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group. , 2005, Clinical lung cancer.
[6] P. Christaki,et al. P-564 Topotecan in combination with carboplatin and etoposide as first line treatment in SCLC patients , 2003 .
[7] J. Jett,et al. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive‐stage small cell lung carcinoma , 2003, Cancer.
[8] J. Hainsworth,et al. Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer. , 2003, The oncologist.
[9] D. Mavroudis,et al. Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study. , 2002, Lung cancer.
[10] K. Mori,et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.
[11] P. Clark,et al. A Phase I Trial of a 5-Day Schedule of Intravenous Topotecan and Etoposide in Previously Untreated Patients with Small-Cell Lung Cancer , 2001, Oncology.
[12] D. Cella,et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Socinski,et al. Phase I trial of topotecan (T) carboplatin (C) and etoposide (E) for extensive stage small cell lung cancer (ES-SCLC) , 2000 .
[14] F. Schramel,et al. Randomised Phase II study of topotecan/cisplatin versus topotecan/etoposide in patients with untreated, extensive disease, small cell lung cancer (SCLC) , 2000 .
[15] P. Bunn,et al. Overview of chemotherapy for small cell lung cancer. , 1997, Seminars in oncology.
[16] J. Glick,et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] D. Payne,et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Ihde,et al. Chemotherapy of Lung Cancer , 1992 .
[19] J. Crawford,et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] K. Suemasu,et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. , 1991, Journal of the National Cancer Institute.
[21] D. Cox,et al. The analysis of binary data , 1971 .
[22] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[23] S. Agelaki,et al. Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study. , 2003, Lung cancer.
[24] C. Stewart. Topoisomerase I interactive agents. , 2001, Cancer chemotherapy and biological response modifiers.
[25] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[26] M. Bychkov,et al. [Chemotherapy of lung cancer]. , 1972, Voprosy onkologii.